這項第三期研究將評估研究藥物 MRTX849 (adagrasib) 對比 docetaxel 在既往接受過治療、帶有 KRAS G12C 突變的轉移性 NSCLC 患者中的療效。
適應症：Metastatic Non Small Cell Lung Cancer、Advanced Non Small Cell Lung Cancer
收案條件
納入條件
- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
- Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- ECOG performance status 0-2
排除條件
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
- Active brain metastases.
- Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。